Skip to main content
Novartis Home

Language & Country Selector for Desktop

language-selector-globe Global | en

Choose Location

  • International
  • Americas
  • Europe
  • Middle East & Africa
  • Asia Pacific
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh

Language & Country Selector for Mobile

language-selector-globe Global

Choose Location

International Americas Europe Middle East & Africa Asia Pacific
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About
      • Board of Directors
        • Joerg Reinhardt
        • Simon Moroney
        • Nancy Andrews
        • Ton Buechner
        • Patrice Bula
        • Elizabeth Doherty
        • Ana de Pro Gonzalo
        • Bridgette Heller
        • Daniel Hochstrasser
        • Frans van Houten
        • Andreas von Planta
        • Charles Sawyers
        • William Winters
        • Charlotte Pamer-Wieser
      • Executive Committee
        • Vasant Narasimhan
        • Shreeram Aradhye
        • James Bradner
        • Victor Bulto
        • Karen Hale
        • Harry Kirsch
        • Rob Kowalski
        • Steffen Lang
        • Klaus Moosmayer
        • Richard Saynor
        • Marie-France Tschudin
        • Lutz Hegemann
        • Michael Willi
        • Kees Roks
      • Strategy
        • People and Culture
        • Data and Digital
      • Products
      • Innovative Medicines
      • Sandoz
      • Operations
        • Global Biotech Cooperations
      • Diversity & Inclusion
        • Equity
        • Diversity & Inclusion Governance and Community
        • Inclusivity
        • Parental Leave
        • Society
      • Quality
        • Audit program
        • Novartis Quality Management System (QMS)
        • Product and patient safety training
        • Regulatory inspections
        • Product recalls
        • Third-party suppliers
      About Novartis
    • Patients and Caregivers
      • Novartis Commitment to Patients and Caregivers
      • Diseases
      • Patient Organization Funding
      • Adverse Event Reporting
      • COVID-19: Patients and Caregivers
      • Stories: Patients Perspectives
      Patients & Caregivers
    • Healthcare Professionals
      • Medical Congresses and Events
        • Abstract summaries for EULAR
        • Abstract summaries for ACR
        • Abstract summaries for EADV
      • Products
      • Novartis Pipeline
      • Managed Access Programs
        • Novartis Gene Therapies Managed Access Program
      • Novartis External Funding
      • Healthcare Professional Resources by Country
      • Investigator-Initiated Trials / Studies
      • Transparency and Disclosure
      • Novartis Medical Information
        • Submit medical enquiry
      Healthcare Professionals
    • Research & Development
      • Novartis Institutes for BioMedical Research
        • Collaborations
        • NIBR Global Scholars Program
      • Technology Platforms
        • Radioligand Therapy
        • Gene Therapy
        • Cell Therapy
      • Research Disease Areas
        • Immuno-oncology research at Novartis
        • Oncology research at Novartis
        • Cardiovascular and metabolic disease research at Novartis
        • Autoimmunity, transplantation and inflammatory disease research at Novartis
        • Ophthalmology research at Novartis
        • Neuroscience Research at Novartis
        • Musculoskeletal Disease Research at Novartis
        • DAx: exploratory disease research at Novartis
      • Research Locations
        • Novartis Institute for Tropical Diseases
      • Novartis Pipeline
      • Translational Medicine
      • Research & Development Approach
      • Stories from our Labs
      • Open Source Science
      Research & Development
    • ESG
      • Access
        • Creating sustainable business models
        • Value-Based Pricing
        • Sub-Saharan Africa
        • Donations
        • Novartis Access Principles
        • Novartis Oncology Access
        • Patents and Licensing
      • Ethics, Risk and Compliance
        • Ethical Behavior
        • Compliance
        • Human Rights
        • Learning and Engagement
        • Risk management
      • Environmental Sustainability
        • Climate
        • Waste
        • Water
      • Global Health
        • Anti-Microbial Resistance (AMR)
        • Avoidable Blindness
        • Chagas Disease
        • Leprosy
        • Malaria
        • Sickle Cell Disease (SCD)
        • Novartis Foundation
      • Diversity & Inclusion
      • Reporting
        • Environmental, Social and Governance (ESG) Index
        • ESG Rating Performance
        • Codes, Policies and Guidelines
        • Materiality Assessment
        • Transparency and Disclosure
        • Targets
        • Positions
      Environmental, Social and Governance
    • Investors
      • Event Calendar
      • Financial Data
        • Novartis Annual Results
        • Novartis Quarterly Results
        • Novartis SEC Filings
        • Product Sales
        • Fixed-Income Securities
        • Expected Currency Impact
      • Share Data & Analysis
        • Share Monitor
        • Dividend Information
        • Share Ownership
        • Share Overview
      • Shareholder Information
        • General Meetings
        • American Depository Receipts (ADR)
        • Share Buy-Back
        • Frequently Asked Questions
      • Company Overview
        • Corporate Governance
      • Novartis Annual Reporting Suite
        • Reporting Archive
        • Publications Order Form
      • ESG
      Investors
    • News
      • News Archive
      • Media Library
      • Stories
      • Subscribe
      News
    • Careers
      • Career Search
      • Our Teams
        • Careers in Commercial
        • Careers in Communications and Advocacy
        • Careers in Consulting
        • Careers in Digital
        • Careers in Health, Safety & Environment
        • Careers in Information Technology (IT)
        • Careers in Medical & Development
        • Careers in People & Organization
        • Careers in Procurement
        • Careers in Research
        • Careers in Strategy
        • Careers in Manufacturing and Supply
        • Ethics, Risk & Compliance (ERC)
        • Careers in Legal
      • Career Programs
        • Community Exploration & Learning Lab (CELL)
      • Early Talent
      • Postdoc Program
        • Andreas Bender, PhD
        • Boxun Lu, PhD
        • The Novartis Innovation Postdoctoral Fellowship
        • The Novartis Discovery Postdoctoral Fellowship
        • Postdoc Research Themes
        • Recognition
        • Postdoc Program Leadership
      • International Careers
      • Learning and Development
      • Well-being
      • Internship Programs
      Careers
    • COVID-19 Information Center
      COVID-19 Novartis response
    • Clinical Trials
      Clinical Trials
    • Partnering
      Partnering
    • Contacts
      Contacts
    Home

Stories

Story Navigation
  • All Topics
  • Discovery
  • From Our Labs
  • Patient Perspectives
  • Access to Healthcare
  • People & Culture
icon
  • SARS-CoV-2, the virus that causes COVID-19
    Discovery
    COVID-19Disease EradicationGlobal Health PartnershipsInfectious DiseasesWorking at Novartis
    Jul 12, 2021
    Building collaborations to fight a pandemic

    Jennifer Leeds offers a behind-the-scenes look at the consortia forming to address COVID-19.

    Discovery
  • Sandoz in Kalwe, India ensures multidrug therapy (MTD) supply to WHO to fight leprosy
    Access to Healthcare
    Access to HealthcareCOVID-19Disease EradicationInfectious DiseasesMalariaSocial Commitment
    Jul 26, 2021
    Ensuring medicine supply to patients during COVID-19

    Read how two sites within the Novartis Technical Operations (NTO) network ensured business continuity at scale and speed in the midst of the COVID-19 pandemic.

    Access to Healthcare
  • Adeno-associated viruses
    Discovery
    Cell and Gene TherapyDrug DiscoveryNeuroscienceGenetic Disease
    Jul 13, 2021
    Collaborating to explore new gene regulation therapies

    Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.

    Discovery
  • The inflammasome
    Chronic IllnessNovartis Institutes for BioMedical ResearchScientific Research
    Jul 12, 2021
    Breaking a vicious cycle of inflammation

    Novartis researchers aim to quash inflammation to treat chronic disease.

  • 3D rendering of COVID-19, the novel coronavirus causing the pandemic
    Discovery
    COVID-19Local ImpactWorking at NovartisClinical TrialsDrug Development
    Jul 14, 2021
    Helping clinical trial patients during a lockdown

    Yan Zhao talks about how her team in China responded to an emerging public health crisis.

    Discovery
  • SARS-CoV-2, the novel coronavirus at the root of the COVID-19 pandemic
    Access to Healthcare
    Access to HealthcareCancerCOVID-19OncologyWorking at NovartisClinical Research
    Jul 21, 2021
    Cancer didn’t stop for COVID-19

    Myriam Mendila describes how Novartis continued supporting cancer patients and healthcare professionals during the pandemic.

    Access to Healthcare
  • 3D rendering of COVID-19, the novel coronavirus causing the pandemic
    Access to Healthcare
    COVID-19Infectious DiseasesInnovationWorking at Novartis
    Jul 30, 2021
    Streamlining systems to respond to COVID-19

    Paul Aliu and his team quickly address requests for Novartis medicines during the pandemic.

    Access to Healthcare
  • 3D rendering of coronavirus disease (COVID-19), the novel coronavirus causing the pand
    Discovery
    COVID-19Disease EradicationInfectious DiseasesWorking at NovartisClinical ResearchClinical Trials
    Jul 15, 2021
    Moving from speculation to science during a pandemic

    Florencia Segal’s experiences prepared her to lead the rapid design of a large COVID-19 clinical trial.

    Discovery
  • 3D rendering of a COVID-19 virus
    Discovery
    COVID-19Disease EradicationInfectious DiseasesWorking at NovartisScientific Research
    Jul 15, 2021
    It takes an R&D village to fight a pandemic

    Gervais Tougas shares his experience working on a Novartis task force dedicated to fighting the COVID-19 pandemic.

    Discovery
  • Coronavirus
    From Our Labs
    COVID-19Disease EradicationInnovationScientific Research
    Jul 20, 2021
    A visual tour of scientific strategies for combating coronavirus

    Researchers around the world are collaborating to provide solutions to immediate and future challenges.

    From Our Labs
  • Europe at night
    People and Culture
    COVID-19DigitalClinical ResearchClinical TrialsClinical ScienceDrug Development
    Aug 10, 2021
    Going the extra mile to keep clinical trials on track during the COVID-19 pandemic

    A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.

    People and Culture
  • Transmission electron microscopic image of an isolate from a case of coronavirus disease (COVID-19)
    Discovery
    Biomedical ResearchCOVID-19Data ScienceDiseasesInfectious DiseasesClinical TrialsBiomedical Science
    Jul 14, 2021
    COVID-19: Answering your top questions

    Novartis CEO Vas Narasimhan answers questions about COVID-19.

    Discovery

Pagination

  • ‹ Previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • › Next page

Novartis

Navigate Novartis
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • COVID-19 Info Center
  • ESG
Explore
  • Stories
  • Diseases
  • Locations
  • Products
  • Novartis Pipeline
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Gyroscope Therapeutics
Footer Bottom
© 2022 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience